Systematic review questions a single stool-test cutoff for bowel cancer in under-50s
A systematic review led by the University of Nottingham has examined how the faecal immunochemical test (FIT) performs for colorectal cancer in symptomatic people under 50. Across 12 studies covering more than 69,000 patients, about 1 in 300 were diagnosed with the disease, a much lower rate than in older adults. The authors conclude that applying the same cutoff to every age group may not be the best approach.
Why younger patients need separate attention
Colorectal cancer is the fourth most common cancer in the UK and the second-leading cause of cancer death, according to Cancer Research UK. Cases diagnosed before the age of 50, known as early-onset disease, have been rising globally, which has sharpened interest in diagnosing younger people sooner.
Most evidence on FIT has come from patients over 50, in whom the underlying risk of colorectal cancer is considerably higher. Far less was known about how the test behaves in younger people who present with symptoms that could have several causes.
What the review did
FIT detects microscopic traces of blood in stool. General practitioners use it in people with symptoms suggestive of bowel cancer. A negative result indicates a very low risk and generally means no further tests are needed. A result at or above the current threshold of 10 leads to urgent referral for further investigation, such as colonoscopy, which is invasive and can be uncomfortable.
The team, led by Professor David Humes of the School of Medicine and the NIHR Nottingham Biomedical Research Centre, collected the available research on FIT in symptomatic patients under 50 and compared the findings with those for patients over 50. The work was supported by international collaborators including COLOREACH-UK and the US charity Fight Colorectal Cancer. It was published in Gut as a systematic review of FIT used in primary care.
Key findings
- Twelve studies met the inclusion criteria, with more than 69,000 symptomatic patients under 50 tested with FIT.
- Colorectal cancer was diagnosed in about 0.35% of these patients.
- In people over 50, the risk was three to seven times higher.
- The authors describe FIT as a good diagnostic test overall, but note that a single threshold of 10 may not perform equally well across ages.
Because the proportion of cancers is lower in younger patients, many more of them would need invasive follow-up tests to identify one case than would older adults. That has implications for patient burden and for the allocation of limited endoscopy capacity.
Limits and next steps
The review pools existing studies, so its conclusions depend on the quality and consistency of the underlying data. The source does not report details of the individual studies, and the authors do not recommend a new threshold. Their conclusion is that more work is needed.
Humes and colleagues point to several priorities: identifying the best FIT cutoff for people under 50, exploring how FIT results could be built into individualised risk prediction models that account for age, and investigating other reasons why FIT may be raised in younger people. Anjee Davis, chief executive of Fight Colorectal Cancer, described the findings as a step towards more tailored diagnosis for under-50s.
For researchers, the review identifies a gap in the evidence base for a growing patient group. It also suggests that diagnostic pathways designed around older populations may need to be refined as early-onset disease becomes more common.
Source: Analysis of over 69,000 younger patients questions one-size-fits-all cutoff for colorectal cancer stool test (Medical Xpress, 19 November 2026).
Image: AI-generated illustration.
Working on this topic? Find a journal for your research or join the discussion on Scholars Post.


